Thalassemia: an overview of 50 years of clinical research.
暂无分享,去创建一个
[1] E. Sariban,et al. Transplanted sickle‐cell disease patients with autologous bone marrow recovery after graft failure develop increased levels of fetal haemoglobin which corrects disease severity , 1995, British journal of haematology.
[2] W. Anderson,et al. Continuous Subcutaneous Administration of Deferoxamine in Patients with Iron Overload , 1977 .
[3] C. Bordignon. Stem-cell therapies for blood diseases , 2006, Nature.
[4] R. Grady,et al. Chelation therapy in beta-thalassemia: an optimistic update. , 2001, Seminars in hematology.
[5] D. Nathan,et al. Hemoglobin F and beta thalassemia. , 1967, Science.
[6] R. Williamson,et al. The severe form of alpha thalassaemia is caused by a haemoglobin gene deletion. , 1974, Nature.
[7] W. Anderson,et al. Isolation and translation of hemoglobin messenger RNA from thalassemia, sickle cell anemia, and normal human reticulocytes. , 1971, The Journal of clinical investigation.
[8] N. Olivieri. The β-Thalassemias , 1999 .
[9] Gonçalo R. Abecasis,et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemia , 2008, Proceedings of the National Academy of Sciences.
[10] J. Hirschhorn,et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and β-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease , 2008, Proceedings of the National Academy of Sciences.
[11] D. Nathan. Regulation of fetal hemoglobin synthesis by cell cycle specific drugs. , 1985, Progress in clinical and biological research.
[12] S. Antonarakis,et al. Nonrandom association of polymorphic restriction sites in the beta-globin gene cluster. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[13] M. Brown,et al. The clinical investigator: bewitched, bothered, and bewildered--but still beloved. , 1997, The Journal of clinical investigation.
[14] G. Stamatoyannopoulos,et al. Induction of human γ globin gene expression by histone deacetylase inhibitors , 2004 .
[15] B. Forget,et al. Defect in messenger RNA for human hemoglobin synthesis in beta thalassemia. , 1971, The Journal of clinical investigation.
[16] D. Faller,et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. , 1993, The New England journal of medicine.
[17] S. Orkin,et al. Hydroxyurea enhances fetal hemoglobin production in sickle cell anemia. , 1984, The Journal of clinical investigation.
[18] I. Wolman. Transfusion Therapy in Cooley's Anemia: Growth and Health as Related to Long‐Range Hemoglobin Levels. A Progress Report , 1964, Annals of the New York Academy of Sciences.
[19] N. Olivieri. The beta-thalassemias. , 1999, The New England journal of medicine.
[20] M. Pirastu,et al. Clinical Research Update: Thalassemias in Sardinia Molecular Pathology, Phenotype‐Genotype Correlation, and Prevention , 1991, The American journal of pediatric hematology/oncology.
[21] S. Brusilow,et al. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. , 1994, Blood.
[22] S. Rivella,et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. , 2000, Nature.
[23] R. Nagel,et al. Permanent and panerythroid correction of murine β thalassemia by multiple lentiviral integration in hematopoietic stem cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[24] M. McCarthy,et al. Genome-wide association studies for complex traits: consensus, uncertainty and challenges , 2008, Nature Reviews Genetics.
[25] H. Varmus,et al. Genetic lesion in homozygous alpha thalassaemia (hydrops fetalis). , 1974, Nature.
[26] D. Nathan,et al. New developments in iron chelators , 2005, Current opinion in hematology.
[27] D. Jamison,et al. Inherited Disorders of Hemoglobin -- Disease Control Priorities in Developing Countries , 2006 .
[28] K. McIntyre,et al. Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. , 1984, The New England journal of medicine.
[29] T. Ley,et al. 5-AZACYTIDINE FOR BETA-THALASSAEMIA? , 1983, The Lancet.
[30] S. Goh,et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin , 2007, Nature Medicine.
[31] S. Orkin,et al. Transcriptional regulation of erythropoiesis: an affair involving multiple partners , 2002, Oncogene.
[32] E. Benz. Clinical management of gene expression. , 1982, The New England journal of medicine.
[33] J. Clegg,et al. Haemoglobin synthesis in beta-thalassaemia. , 1968, Nature.
[34] B. Thorell,et al. ABSORPTION SPECTRA OF INCLUSION BODIES IN BETA-THALASSEMIA. , 1965, Blood.
[35] Michel Sadelain,et al. Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin , 2000, Nature.
[36] R. Galanello,et al. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. , 2003, Blood.
[37] Charles B. Hall,et al. Transferrin therapy ameliorates disease in β-thalassemic mice , 2010, Nature Medicine.
[38] P. Marks,et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease , 2007, British journal of haematology.
[39] C. Pegelow,et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. , 2003, JAMA.
[40] P. Leboulch,et al. A phase I/II clinical trial of beta-globin gene therapy for beta-thalassemia. , 2005, Annals of the New York Academy of Sciences.
[41] Y. Kan,et al. Prenatal diagnosis of homozygous β-thalassæmia , 1975, The Lancet.
[42] T. Maniatis,et al. Molecular cloning and characterization of the human beta-like globin gene cluster. , 1980, Cell.
[43] D. J. Weatherall,et al. Phenotype—genotype relationships in monogenic disease: lessons from the thalassaemias , 2001, Nature Reviews Genetics.
[44] J. Clegg,et al. Haemoglobin Synthesis in α-Thalassaemia (Haemoglobin H Disease) , 1967, Nature.
[45] T. Maniatis,et al. Molecular cloning and characterization of the human β-like globin gene cluster , 1980, Cell.
[46] F. Barton,et al. Design of the multicenter study of hydroxyurea in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea. , 1995, Controlled clinical trials.
[47] Yusuke Nakamura,et al. A genome-wide association identified the common genetic variants influence disease severity in β0-thalassemia/hemoglobin E , 2009, Human Genetics.
[48] M. Cazzola,et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study , 2007, European journal of haematology.
[49] Serena Sanna,et al. Amelioration of Sardinian beta0 thalassemia by genetic modifiers. , 2009, Blood.
[50] P. Marks,et al. Decreased globin messenger RNA in thalassemia detected by molecular hybridization. , 1973, Proceedings of the National Academy of Sciences of the United States of America.
[51] J. Clegg,et al. Globin Synthesis in Thalassaemia: An in vitro Study , 1965, Nature.
[52] David A. Williams,et al. Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse , 1984, Nature.
[53] Y. Kan,et al. Polymorphism of DNA sequence adjacent to human beta-globin structural gene: relationship to sickle mutation. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[54] J. D. Heywood,et al. Amino Acids: Incorporation into α- and β-Chains of Hemoglobin by Normal and Thalassemic Reticulocytes , 1964, Science.
[55] C. Hershko,et al. Heart cells in culture: a model of myocardial iron overload and chelation. , 1985, The Journal of laboratory and clinical medicine.
[56] P. Marks,et al. Hemoglobin synthesis in thalassemia. , 1971, Series haematologica.
[57] S. Rivella,et al. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. , 2003, Blood.
[58] J. H. MacMillan,et al. Survival in medically treated patients with homozygous beta-thalassemia. , 1994, The New England journal of medicine.
[59] F. Locatelli. Reduced-intensity regimens in allogeneic hematopoietic stem cell transplantation for hemoglobinopathies. , 2006, Hematology. American Society of Hematology. Education Program.
[60] E. Bakker,et al. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients. , 2004, Haematologica.
[61] S. Orkin,et al. Linkage of beta-thalassaemia mutations and beta-globin gene polymorphisms with DNA polymorphisms in human beta-globin gene cluster. , 1982, Nature.
[62] S. Rivella,et al. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. , 2002, Blood.
[63] K. McIntyre,et al. Influence of cell cycle phase-specific agents on simian fetal hemoglobin synthesis. , 1985, The Journal of clinical investigation.
[64] Jeffrey C. Miller,et al. Highly efficient endogenous human gene correction using designed zinc-finger nucleases , 2005, Nature.
[65] M. Andreani,et al. Bone Marrow Transplantation in Adults with Thalassemia: Treatment and Long‐Term Follow‐Up , 2005, Annals of the New York Academy of Sciences.
[66] Vip Viprakasit,et al. A Regulatory SNP Causes a Human Genetic Disease by Creating a New Transcriptional Promoter , 2006, Science.
[67] D. Jamison,et al. Disease Control Priorities in Developing Countries , 1993 .
[68] D. Housman,et al. Quantitative deficiency of chain-specific globin messenger ribonucleic acids in the thalassemia syndromes. , 1973, Proceedings of the National Academy of Sciences of the United States of America.
[69] G. Stamatoyannopoulos,et al. Induction of human gamma globin gene expression by histone deacetylase inhibitors. , 2004, Blood.
[70] J. Clegg,et al. Haemoglobin Synthesis in β-Thalassaemia , 1968, Nature.
[71] M. Cappellini,et al. Oral iron chelators. , 2009, Annual review of medicine.
[72] 5—Azacytidine selectively increases globin synthesis in a patient with thalassemia , 1983 .
[73] P. Rebulla. Blood transfusion in beta thalassaemia major , 1995, Transfusion medicine.
[74] R. Grady,et al. Chelation therapy in β-thalassemia: An optimistic update☆ , 2001 .
[75] A. Schechter,et al. 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. , 1983, Blood.
[76] J. Hirschhorn,et al. Supporting Online Material Materials and Methods Figs. S1 to S10 Tables S1 to S7 References Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-specific Repressor Bcl11a , 2022 .
[77] Dana Carroll,et al. Gene targeting using zinc finger nucleases , 2005, Nature Biotechnology.
[78] D. Faller,et al. Delay in the fetal globin switch in infants of diabetic mothers. , 1985, The New England journal of medicine.
[79] Jérôme Larghero,et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia , 2010, Nature.
[80] D. Weatherall,et al. CHELATION REGIMENS WITH DESFERRIOXAMINE , 1977, The Lancet.
[81] S. Rivella,et al. Successful treatment of murine β-thalassemia intermedia by transfer of the human β-globin gene , 2002 .
[82] W. Bodmer,et al. 5-AZACYTIDINE FOR BETA-THALASSAEMIA? , 1983, The Lancet.
[83] S. J. Chen,et al. Butyrate infusions in the ovine fetus delay the biologic clock for globin gene switching. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[84] P. Chiusolo,et al. Reliability of leukostasis grading score to identify patients with high‐risk hyperleukocytosis , 2009, American journal of hematology.
[85] B. Thorell,et al. Brief Report: Absorption Spectra of Inclusion Bodies in β-Thalassemia , 1965 .
[86] Y. Kan,et al. Mild thalassemia: the result of interactions of alpha and beta thalassemia genes. , 1970, The Journal of clinical investigation.
[87] J. Tripp,et al. Magnetic-susceptibility measurement of human iron stores. , 1982, The New England journal of medicine.
[88] P. Vossough,et al. Hydroxyurea in the treatment of major β-thalassemia and importance of genetic screening , 2004, Annals of Hematology.
[89] A. Bank. Regulation of human fetal hemoglobin: new players, new complexities. , 2006, Blood.
[90] D. Weatherall. History of genetic disease: Thalassaemia: the long road from bedside to genome , 2004, Nature Reviews Genetics.
[91] J. Hobbins,et al. In utero diagnosis of: hemoglobinopathies. Hemoglobin synthesis in fetal red cells. , 1974, The New England journal of medicine.
[92] Noninvasive quantitation of liver iron in dogs with hemochromatosis using dual-energy CT scanning. , 1982, Investigative radiology.
[93] S. Orkin,et al. Linkage of β-thalassaemia mutations and β-globin gene polymorphisms with DNA polymorphisms in human β-globin gene cluster , 1982, Nature.
[94] D. Nathan. Thalassemia: The Continued Challenge , 2005 .
[95] Y. Kan,et al. Successful application of prenatal diagnosis in a pregnancy at risk for homozygous beta-thalassemia. , 1975, The New England journal of medicine.
[96] S. Orkin,et al. Partial deletion of beta-globin gene DNA in certain patients with beta 0-thalassemia. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[97] M L Terrin,et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. , 1995, The New England journal of medicine.
[98] Stuart H. Orkin,et al. Developmental and species-divergent globin switching are driven by BCL11A , 2009, Nature.
[99] Marius Wernig,et al. Treatment of Sickle Cell Anemia Mouse Model with iPS Cells Generated from Autologous Skin , 2007, Science.
[100] A. Stretton,et al. Genetic basis of the thalassaemia diseases. , 1959, Nature.
[101] D. Zwiers,et al. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[102] H. Lazarus,et al. The molecular basis of alpha-thalassemias: frequent occurrence of dysfunctional alpha loci among non-Asians with Hb H disease. , 1979, Cell.
[103] M. Becker,et al. PREVENTION OF BONE MALFORMATIONS AND CARDIOMEGALY IN COOLEY'S ANEMIA BY EARLY HYPERTRANSFUSION REGIMEN * , 1969, Annals of the New York Academy of Sciences.
[104] D. Sonakul,et al. Cardiac pathology in 76 thalassemic patients. , 1988, Birth defects original article series.
[105] A. Cnaan,et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. , 2004, Haematologica.
[106] E. Rachmilewitz,et al. MEDICAL PROGRESS : β-thalassemia , 2005 .
[107] O. Platt,et al. Hydroxyurea for the treatment of sickle cell anemia. , 2008, The New England journal of medicine.
[108] D. Nathan,et al. New approaches to the transfusion management of thalassemia. , 1980, Blood.
[109] P. Fessas. Inclusions of hemoglobin erythroblasts and erythrocytes of thalassemia. , 1963, Blood.
[110] J. Hobbins,et al. In utero diagnosis of hemoglobinopathies. Technic for obtaining fetal blood. , 1974, The New England journal of medicine.
[111] P. Musgrove,et al. Inherited Disorders of Hemoglobin , 2006 .
[112] E. Neufeld. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. , 2006, Blood.
[113] E. Neufeld,et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial , 2003, The Lancet.
[114] S. Antonarakis,et al. Prenatal diagnosis using DNA polymorphisms. Report on 95 pregnancies at risk for sickle-cell disease or beta-thalassemia. , 1983, The New England journal of medicine.
[115] T. S. St. Pierre,et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. , 2005, Blood.
[116] J. B. Clegg,et al. The thalassaemia syndromes , 1965 .
[117] Y. Kan,et al. Prenatal diagnosis of homozygous beta-thalassaemia. , 1975, Lancet.
[118] H. Lodish,et al. Beta thalassemia and translation of globin messenger RNA. , 1971, Proceedings of the National Academy of Sciences of the United States of America.
[119] S. Shurin,et al. Reassessment of the use of desferrioxamine B in iron overload. , 1976, The New England journal of medicine.
[120] H. Lazarus,et al. Application of endonuclease mapping to the analysis and prenatal diagnosis of thalassemias caused by globin-gene deletion. , 1978, The New England journal of medicine.
[121] D. Faller,et al. Butyrate derivatives. New agents for stimulating fetal globin production in the beta-globin disorders. , 1994, The American journal of pediatric hematology/oncology.
[122] J. H. MacMillan,et al. Survival in Medically Treated Patients with Homozygous β-Thalassemia , 1994 .
[123] Shinya Yamanaka,et al. Induced pluripotent stem cells and reprogramming: seeing the science through the hype , 2009, Nature Reviews Genetics.
[124] P. Fessas. Inclusions of Hemoglobin in Erythroblasts and Erythrocytes of Thalassemia , 1963 .
[125] Simon Heath,et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15 , 2007, Nature Genetics.
[126] D J Pennell,et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major , 2009, Circulation.
[127] R. Ljung,et al. HIGH-DOSE INTRAVENOUS GAMMABLOBULIN: A CAUTIONARY NOTE , 1985, The Lancet.
[128] D. Samid,et al. Increased fetal hemoglobin in patients receiving sodium 4-phenylbutyrate. , 1992, The New England journal of medicine.
[129] H. Lazarus,et al. The molecular basis of α-thalassemias: Frequent occurrence of dysfunctional α loci among non-Asians with Hb H disease , 1979, Cell.
[130] D. Higgs. Gene regulation in hematopoiesis: new lessons from thalassemia. , 2004, Hematology. American Society of Hematology. Education Program.
[131] S. Woo. Policy statement of the American Society of Gene Therapy on reporting of patient adverse events in gene therapy trials. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[132] N. Olivieri,et al. Extended therapy with intravenous arginine butyrate in patients with beta-hemoglobinopathies. , 1995, The New England journal of medicine.
[133] Yi Fang Liu,et al. Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin. , 2006, Blood.
[134] P. Marks,et al. Hemoglobins A and F: Formation in Thalassemia and Other Hemolytic Anemias , 1964, Science.
[135] Jonathan D. Powell,et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. , 2009, The New England journal of medicine.
[136] Swee Lay Thein,et al. Molecular therapies in β‐thalassaemia , 2007, British journal of haematology.
[137] G. Daley. Stem cells: roadmap to the clinic. , 2010, The Journal of clinical investigation.
[138] M. Sadelain,et al. Current status of globin gene therapy for the treatment of β‐thalassaemia , 2008, British journal of haematology.
[139] R. Gunn,et al. Thalassemia: the consequences of unbalanced hemoglobin synthesis. , 1966, The American journal of medicine.
[140] D. Loukopoulos,et al. DISCUSSION PAPER PRENATAL DIAGNOSIS OF THALASSEMIA MAJOR IN GREECE: EVALUATION OF THE FIRST LARGE SERIES OF ATTEMPTS * , 1980, Annals of the New York Academy of Sciences.
[141] D. Mohanty,et al. Carrier screening for beta-thalassemia during pregnancy in India: a 7-year evaluation. , 2008, Genetic testing.
[142] Y. Kan,et al. Organization of the alpha-globin genes in the Chinese alpha-thalassemia syndromes. , 1979, The Journal of clinical investigation.
[143] M. Chandy. Stem cell transplantation in India , 2008, Bone Marrow Transplantation.
[144] A. Hoffbrand,et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. , 1998, Blood.
[145] C. McLaren,et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. , 1994, The New England journal of medicine.
[146] M. Sutton,et al. Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin. , 2007, Blood.
[147] D. Weatherall,et al. FIRST-TRIMESTER FETAL DIAGNOSIS FOR HAEMOGLOBINOPATHIES: THREE CASES , 1982, The Lancet.
[148] G. Stamatoyannopoulos. Control of globin gene expression during development and erythroid differentiation. , 2005, Experimental hematology.
[149] D. Nathan. The several Cs of translational clinical research. , 2005, The Journal of clinical investigation.
[150] D. Weatherall,et al. Haemoglobin E beta thalassaemia in Sri Lanka. , 2005, Lancet.
[151] P. Leboulch,et al. A Phase I/II Clinical Trial of β‐Globin Gene Therapy for β‐Thalassemia , 2005 .
[152] G. Stamatoyannopoulos,et al. Arabinosylcytosine induces fetal hemoglobin in baboons by perturbing erythroid cell differentiation kinetics. , 1984, Science.
[153] T. Ganz,et al. The Role of Hepcidin in Iron Metabolism , 2009, Acta Haematologica.
[154] Tomas Ganz,et al. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. , 2003, Blood.
[155] David Baltimore,et al. Chimeric Nucleases Stimulate Gene Targeting in Human Cells , 2003, Science.
[156] H. Bard,et al. Relative rates of fetal hemoglobin and adult hemoglobin synthesis in cord blood of infants of insulin-dependent diabetic mothers. , 1985, Pediatrics.